Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-102 in children and adolescents with Fabry disease
ISRCTN14012649Phase 3Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Safety, Efficacy - renal function and 5 more. Started Apr 2025; status: recruiting.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on ISRCTN14012649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14012649.